Name | terazosin |
---|---|
Synonyms |
Terazosin Hydrochloride
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone MFCD00467965 |
Description | Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).Target: Alpha-1 Adrenergic ReceptorTerazosin is selective for alpha 1A-adrenoceptors which appear to dominate in the human prostate; the therapeutic relevance of this selectivity remains to be assessed in clinical studies [1]. Administration of terazosin 1 mg orally for 28 d. Terazosin initially shifted the dose-response curve of phenylephrine to the right, with a significant increase in ED50 for phenylephrine from a control value of 102 to 759 ng/min on day 1 of terazosin (P < 0.001). The mean Kd of terazosin was estimated as 11 +/- 15 nM in the first few days of treatment. This study demonstrates that pharmacological tolerance to the alpha 1-adrenoceptor blocking action of terazosin occurs in man and may be responsible for loss in efficacy with chronic therapy [2]. |
---|---|
Related Catalog | |
References |
Density | 1.332 g/cm3 |
---|---|
Boiling Point | 664.5ºC at 760 mmHg |
Melting Point | 281-283°C |
Molecular Formula | C19H25N5O4 |
Molecular Weight | 387.43300 |
Flash Point | 355.7ºC |
Exact Mass | 387.19100 |
PSA | 103.04000 |
LogP | 1.64090 |
Storage condition | -20°C Freezer |
Water Solubility | H2O: 25 mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn: Harmful; |
Risk Phrases | R22 |
Safety Phrases | S26 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | TK8044925 |
~% 63590-64-7 |
Literature: US2007/161791 A1, ; Page/Page column 2; 3-4 ; |
~% 63590-64-7 |
Literature: US6313293 B1, ; |
~% 63590-64-7 |
Literature: Synthetic Communications, , vol. 34, # 10 p. 1881 - 1884 |
Precursor 3 | |
---|---|
DownStream 0 |